Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-05-31
2011-05-31
Cordero Garcia, Marcela M (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
Reexamination Certificate
active
07951777
ABSTRACT:
The present invention is concerned with composition and methods for treatment of certain cardiovascular conditions. In particular it is concerned with prophylactic or therapeutic treatment of myocardial fibrosis or associated conditions by administering compositions comprising vasoactive intestinal peptide (VIP) and/or active fragments) thereof.
REFERENCES:
patent: 3862927 (1975-01-01), Said et al.
patent: 3880826 (1975-04-01), Said et al.
patent: 4835252 (1989-05-01), Musso et al.
patent: 4939224 (1990-07-01), Musso et al.
patent: 6217886 (2001-04-01), Onyuksel et al.
patent: 2005/0075290 (2005-04-01), Gandhi
patent: WO-88/03928 (1988-06-01), None
patent: WO-01/34088 (2001-05-01), None
patent: WO-02/43746 (2002-06-01), None
patent: WO2005120545 (2005-12-01), None
patent: WO2007065226 (2007-06-01), None
Markos et al. An Evaluation of the Efficacy of Vasoactive Intestinal Polypeptide Antagonists in vivo in the Anaesthetized Dog. Pharmacology, 2002. vol. 66, pp. 206-210.
Davis et al., “The Effects of a High Sodium Diet on the Metabolism and Secretion of Vasoactive Intestinal Peptide in the Rabbit,” Journal of Physiology (1992), 451, pp. 17-23.
Delgado et al., “Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease,” Nature Medicine, (2001), vol. 7, No. 5, pp. 563-568.
Duggan et al., “Angiotensin-Converting Enzyme Inhibition with Enalapril Increases the Cardiac Concentration of Vasoactive Intestinal Peptide,” Annals of the New York Academy of Sciences (1996), vol. 805, pp. 713-716.
Hughes et al., “Arterial myogenic properties of the spontaneously hypertensive rat,” Experimental Physiology (2002), vol. 87.5, pp. 527-534.
Humphrey et al., “Hepatic and Pulmonary Clearance of Exogenous Vasoactive Intestinal Peptide in the Rat,” Gastroenterology (1979), vol. 77(1), pp. 55-60.
International Search Report, International Application No. PCT/AU2005/000835.
Kalfin et al., “Protective Role of Intracoronary Vasoactive Intestinal Peptide in Ischemic and Reperfused Myocardium,” The Journal of Pharmacology and Experimental Therapeutics (1994), vol. 268, No. 2, pp. 952-268.
Pechanova et al., “Positive therapeutic effects of red wine polyphenols in pexperimental hypertension,” Bulletin OIV, 859-860, 678-697 (English translation) (an English translation is provided.).
Sacerdote et al., “Vasoactive Intestinal Peptide 1-12: A Ligand for the CD4 (T4)/Human Immunodeficiency Virus Receptor,” Journal of Neuroscience Research (1987), vol. 18, pp. 102-107.
Saetrum Opgaard et al., “Vasoactive intestinal peptide has a direct positive inotropic effect on isolated human myocardial trabeculae,” Clinical Science (2001), vol. 101 pp. 637-643.
Sole, et al., “A Possible Change in the Rate-Limiting Step for Cardiac Norepinephrine Synthesis in the Cardiomyopathic Syrian Hamster,” Circulation Research (Dec. 1977), vol. 41, No. 6, pp. 814-817.
Tsybouleva et al. “Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy,” Circulation Mar 16, 2004, 109(10), pp. 1284-1291 (Abstract).
Tsybouleva et al. “Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy,” Circulation Mar 16, 2004, 109(10), pp. 1284-1291.
Unverferth et al., “Effect of vasoactive intestinal polypeptide on the canine cardiovascular system,” J. Laboratory & Clinical Medicine (1985), vol. 106, No. 5, pp. 542-550.
Unverferth et al., “The evolution of β-adrenergic dysfunction during the induction of canine cobalt cardiomyopathy,” Cardiovascular Research (1984), 18, pp. 44-50.
Ye et al., “Early myocardial fibrosis is associated with depletion of vasoactive intestinal peptide in rat heart,” Experimental Physiology (2002), vol. 87.5, pp. 539-546.
Ye et al., “Vasopeptidase inhibition reverses myocardial vasoactive intestinal peptide depletion and decreases fibrosis in salt sensitive hypertension.” European Journal of Pharmacology, (2004), vol. 485, pp. 235-242.
Ye et al., “Myocardial vasoactive intestinal peptide and fibrosis induced by nitric oxide snythase inhibition in the rat,” Scandinavian Physiological Society, (2003), vol. 179, pp. 353-360.
Cordero Garcia Marcela M
Goodwin & Procter LLP
Vectus Biosystems Limited
LandOfFree
Compositions and methods for treatment of cardiovascular... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for treatment of cardiovascular..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for treatment of cardiovascular... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2699336